Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2019, Article ID 9205851, 12 pages
https://doi.org/10.1155/2019/9205851
Research Article

Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo

Wei Wang,1,2,3,4 Zhenhua Hu,2,3 Yu Huang,1,2,3 Huilin Zheng,2,3 Qiang Sun,1,2,3 Qifan Yang,1,2,3 Yuan Zhang,1,2,3 Linshi Zhang,1,2,3 and Weilin Wang1,2,3

1Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, China
2Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, The First Affiliated Hospital, School of Medicine, Zhejiang University, China
3Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital, School of Medicine, Zhejiang University, China
4Department of Gastrointestinal Surgery, Shaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing 312000, Zhejiang, China

Correspondence should be addressed to Weilin Wang; nc.ude.ujz@maw

Received 1 November 2018; Accepted 27 February 2019; Published 25 March 2019

Academic Editor: Giandomenico Roviello

Copyright © 2019 Wei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. I. Wistuba and A. F. Gazdar, “Gallbladder cancer: lessons from a rare tumour,” Nature Reviews Cancer, vol. 4, no. 9, pp. 695–706, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Hundal and E. A. Shaffer, “Gallbladder cancer: epidemiology and outcome,” Journal of Clinical Epidemiology, vol. 6, no. 1, pp. 99–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Li, Z. Zhang, X. Li et al., “Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway,” Nature Genetics, vol. 46, no. 8, pp. 872–876, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. PDQ Adult Treatment Editorial Board, “Gallbladder cancer treatment (PDQ®): health professional version,” PDQ Cancer Information Summaries, 2019, https://www.ncbi.nlm.nih.gov/books/NBK65933/. View at Google Scholar
  5. L. M. Stinton and E. A. Shaffer, “Epidemiology of gallbladder disease: cholelithiasis and cancer,” Gut and Liver, vol. 6, no. 2, pp. 172–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. P. G. Natali, M. R. Nicotra, A. Bigotti et al., “Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues,” International Journal of Cancer, vol. 45, no. 3, pp. 457–461, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. Mitri, T. Constantine, and R. O'Regan, “The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy,” Chemotherapy Research and Practice, vol. 2012, Article ID 743193, 7 pages, 2012. View at Publisher · View at Google Scholar
  8. J. Y. Kim, Y. Cho, E. Oh et al., “Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer,” Cancer Letters, vol. 379, no. 1, pp. 39–48, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. E. E. Cilek, H. Ozturk, and B. Gur Dedeoglu, “Construction of miRNA-miRNA networks revealing the complexity of miRNA-mediated mechanisms in trastuzumab treated breast cancer cell lines,” PLoS ONE, vol. 12, no. 10, 2017. View at Google Scholar · View at Scopus
  10. Y.-J. Bang, E. Van Cutsem, and A. Feyereislova, “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Marty, F. Cognetti, D. Maraninchi et al., “Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer administered as first-line treatment: the m77001 study group,” Journal of Clinical Oncology, vol. 23, no. 19, pp. 4265–4274, 2005. View at Publisher · View at Google Scholar
  12. K. Kiguchi, S. Carbajal, K. Chan et al., “Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma,” Cancer Research, vol. 61, no. 19, pp. 6971–6976, 2001. View at Google Scholar · View at Scopus
  13. D. Jelovac and L. A. Emens, “HER2-directed therapy for metastatic breast cancer,” Oncology (Williston Park), vol. 27, no. 3, pp. 166–175, 2013. View at Google Scholar
  14. W. Yang, A. Raufi, and S. J. Klempner, “Targeted therapy for gastric cancer: molecular pathways and ongoing investigations,” Biochimica et Biophysica Acta, vol. 1846, no. 1, pp. 232–237, 2014. View at Publisher · View at Google Scholar
  15. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Sorscher, “Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab,” Cancer Management and Research, vol. 9, pp. 1–3, 2013. View at Google Scholar · View at Scopus
  17. A.-R. Nam, J.-W. Kim, Y. Cha et al., “Therapeutic implication of HER2 in advanced biliary tract cancer,” Oncotarget , vol. 7, no. 36, pp. 58007–58021, 2016. View at Google Scholar · View at Scopus
  18. K. Ito, M. Mitsunaga, S. Arihiro et al., “Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms,” BMC Cancer, vol. 16, no. 1, p. 37, 2016. View at Google Scholar · View at Scopus
  19. S. Harada, M. Yanagisawa, S. Kaneko et al., “Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model,” Molecular and Clinical Oncology, vol. 3, no. 5, pp. 987–994, 2015. View at Publisher · View at Google Scholar
  20. H. Kalekou and D. Miliaras, “Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma,” Journal of Gastroenterology and Hepatology, vol. 19, no. 7, pp. 812–818, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Taniyama, K. Ishida, T. Toda et al., “Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas,” Breast Cancer, vol. 15, no. 3, pp. 231–240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. S. E. Wang and R.-J. Lin, “MicroRNA and HER2-overexpressing cancer,” MicroRNA (Shariqah, United Arab Emirates), vol. 2, no. 2, pp. 137–147, 2013. View at Google Scholar · View at Scopus
  23. S. Kan, S. Koido, M. Okamoto et al., “Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine,” Oncology Reports, vol. 34, no. 1, pp. 504–510, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Kan, S. Koido, M. Okamoto et al., “Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells,” BMC Cancer, vol. 15, no. 1, p. 726, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. A. D. Thor, S. Liu, S. Edgerton et al., “Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer,” Journal of Clinical Oncology, vol. 18, no. 18, pp. 3230–3239, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Lohrisch and M. Piccart, “An overview of HER2,” Seminars in Oncology, vol. 28, no. 6, pp. 3–11, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Cicenas, P. Urban, W. Küng et al., “Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients,” European Journal of Cancer, vol. 42, no. 5, pp. 636–645, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Yamashita, N. Saito, S. Zhao et al., “Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells,” Experimental Cell Research, vol. 366, no. 1, pp. 34–40, 2018. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Perrier, J. Gligorov, G. Lefèvre, and M. Boissan, “The extracellular domain of Her2 in serum as a biomarker of breast cancer,” Laboratory Investigation, vol. 98, no. 6, pp. 696–707, 2018. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Oono, T. Kuwata, K. Takashima et al., “Clinicopathological features and endoscopic findings of HER2-positive gastric cancer,” Surgical Endoscopy, vol. 32, no. 9, pp. 3964–3971, 2018. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Dominguez, M. Rosa, T. B. George, J. Pimiento, G. Y. Lauwers, and D. Coppola, “Evaluation of expression of human epidermal growth factor receptor 2 (HER2) in gastric and gastroesophageal junction adenocarcinoma using IHC and dual-ISH,” Anticancer Reseach, vol. 38, no. 1, pp. 367–372, 2018. View at Google Scholar · View at Scopus
  32. H. Yoshida, K. Shimada, T. Kosuge, and N. Hiraoka, “A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status,” Virchows Archiv, vol. 468, no. 4, pp. 431–439, 2016. View at Publisher · View at Google Scholar · View at Scopus